[go: up one dir, main page]

BR9808515A - Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos - Google Patents

Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos

Info

Publication number
BR9808515A
BR9808515A BR9808515-8A BR9808515A BR9808515A BR 9808515 A BR9808515 A BR 9808515A BR 9808515 A BR9808515 A BR 9808515A BR 9808515 A BR9808515 A BR 9808515A
Authority
BR
Brazil
Prior art keywords
treatment
prophylaxis
prostate cancer
selective estrogen
receptor modulators
Prior art date
Application number
BR9808515-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9808515A publication Critical patent/BR9808515A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
BR9808515-8A 1997-04-09 1998-04-07 Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos BR9808515A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
BR9808515A true BR9808515A (pt) 2001-06-19

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808515-8A BR9808515A (pt) 1997-04-09 1998-04-07 Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos

Country Status (16)

Country Link
EP (1) EP0975629A4 (xx)
JP (1) JP2001518900A (xx)
KR (1) KR20010006218A (xx)
CN (1) CN1259944A (xx)
AU (1) AU6966198A (xx)
BR (1) BR9808515A (xx)
CA (1) CA2286204A1 (xx)
EA (1) EA199900914A1 (xx)
HU (1) HUP0003589A3 (xx)
ID (1) ID24358A (xx)
IL (1) IL132277A0 (xx)
NO (1) NO994903L (xx)
PL (1) PL336205A1 (xx)
TR (1) TR199902701T2 (xx)
WO (1) WO1998045288A1 (xx)
ZA (1) ZA982819B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US7825107B2 (en) * 2006-05-22 2010-11-02 Hormos Medical Ltd. Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors
EA022760B1 (ru) 2007-10-16 2016-02-29 Репрос Терапьютикс Инк. Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
MA38325B1 (fr) 2013-02-19 2019-03-29 Novartis Ag Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
PL336205A1 (en) 2000-06-05
AU6966198A (en) 1998-10-30
ID24358A (id) 2000-07-13
HUP0003589A3 (en) 2002-02-28
EP0975629A4 (en) 2001-03-21
NO994903L (no) 1999-12-09
JP2001518900A (ja) 2001-10-16
CA2286204A1 (en) 1998-10-15
WO1998045288A1 (en) 1998-10-15
NO994903D0 (no) 1999-10-08
EP0975629A1 (en) 2000-02-02
ZA982819B (en) 1999-10-04
IL132277A0 (en) 2001-03-19
KR20010006218A (ko) 2001-01-26
EA199900914A1 (ru) 2000-04-24
HUP0003589A2 (hu) 2002-01-28
TR199902701T2 (xx) 2000-02-21
CN1259944A (zh) 2000-07-12

Similar Documents

Publication Publication Date Title
BR9809389A (pt) Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
AU674477B2 (en) Heterocyclic-cyclic amine derivatives
GB9514473D0 (en) Chemical compounds
KR100263496B1 (ko) 탁솔 유도체 및 이의 제조방법
EP1009755A4 (en) STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME
BR9808515A (pt) Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
KR20000005379A (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
GB9727521D0 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
PL341050A1 (en) Heterocyclic cytoxic agents
LU92263I2 (fr) Imépitoïne et ses dérivés pharmaceutiquement acceptables (PEXION)
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
PT1189923E (pt) Derivados aromaticos e heterociclicos de fitosterois e/ ou fitostanois para utilizacao no tratamento ou prevencao de doenca cardiovascular
AUPR118000A0 (en) Therapeutic molecules and methods
AU2393997A (en) Alpha1-adrenergic receptor antagonists
EA199900910A1 (ru) Профилактика рака молочной железы селективными модуляторами рецепторов эстрогена
YU46302A (sh) Supstituisani piroli
MX9701327A (es) Metodos para inhibir el cancer endometrial.
NO994107L (no) Preparater for behandling eller forhindring av prostatakreft
EP0551952A3 (en) 17-aryl-substituted steroidal compounds active on the cardiovascular system
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9806036A (es) Compuestos para inhibir tumores en el colon.
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents
MX9603797A (es) Agentes terapeuticos para su uso en la terapia del cancer.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]